Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative Acute Effects of LSD, Psilocybin and Mescaline
NCT04227756Phase 1Completed
- Sponsor
- University Hospital Basel
- Start
- May 2020
- Primary completion
- Sep 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Lysergide, psilocybin and mescaline (4 arms), sponsored by University Hospital Basel. Primary endpoints: 5 Dimensions of Altered States of Consciousness at 18 months and fMRI resting state functional connectivity at 18 months. Started May 2020; status: completed.
02
Drugs
Lysergidepsilocybinmescaline
Beyond the preview
Go deeper on NCT04227756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04227756.